Sarah Diepstraten

Experts / Sarah Diepstraten

Sarah Diepstraten

Senior Research Officer, Blood Cells and Blood Cancer Division, Walter and Eliza Hall Institute

Sarah Diepstraten completed her PhD at La Trobe University in molecular genetics and developmental biology. She is now a post-doctoral scientist at the Walter and Eliza Hall Institute. Her research focuses on understanding how blood cancers become resistant to therapy and how this can be overcome. She develops genetic engineering approaches (CRISPR) to find genes involved in drug resistance. She has also taught in undergraduate science courses at La Trobe University and Melbourne University, and is passionate about science education.

How does the drug abemaciclib treat breast cancer?

The anti-cancer drug abemaciclib (also known as Vernezio) has this month been added to the Australian Pharmaceutical Benefits Scheme (PBS) to treat certain types of breast cancer.

How does the drug abemaciclib treat breast cancer?

The anti-cancer drug abemaciclib (also known as Vernezio) has this month been added to the Australian Pharmaceutical Benefits Scheme (PBS) to treat certain types of breast cancer.

By Sarah Diepstraten, Dr John La Marca